Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPRAB study – MITO 36
2017-004690-14Phase 2Active
- Sponsor
- Policlinico Gemelli
- Start
- May 2021
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin and pegylated liposomal doxorubicin in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Policlinico Gemelli. Primary endpoints: Objective response rate, Response evaluation by RECIST v1.1 and 1 more. Started May 2021; status: active.
02
Drugs
trabectedinpegylated liposomal doxorubicin
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2017-004690-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004690-14.